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Abstract
Background & Aims—Heme oxygenase-1 (HO-1) is an antioxidant defense and key
cytoprotective enzyme, which is repressed by Bach1. MicroRNA-122 (miR-122) is specifically
expressed and highly abundant in human liver and required for replication of hepatitis C virus (HCV)
RNA. This study was to assess whether a specific miR-122 antagomir down-regulates HCV protein
replication and up-regulates HO-1.
Methods—We transfected antagomir of miR-122, 2′-O-methyl-mimic miR-122, or non-specific-
control antagomir (NSCA) into wild type Huh-7 cells or Huh-7 stably replicating HCV subgenomic
core-NS3 (CNS3 replicon cells), or NS3-5B (9–13 replicon cells).
Results—Antagomir of miR-122 reduced the abundance of HCV-RNA by 64% in CNS3, and by
84% in 9–13 cells. In contrast, transfection with 2′-O-methlyl-mimic miR-122 increased HCV levels
up to 2.5-fold; transfection with NSCA did not change the level of HCV. Antagomir of miR-122 also
decreased Bach1 and increased HO-1 mRNA levels in CNS3, 9–13, and WT Huh-7 cells. Increasing
HO-1 by silencing Bach1 with 50 nM Bach1-siRNA or by treatment with 5 μM cobalt protoporphyrin
or heme (known inducers of HO-1) decreased HCV RNA and protein by 50% in HCV replicon cells.
Conclusions—Down-regulation of HCV replication using an antagomir targeted to miR-122 is
effective, specific, and selective. Increasing HO-1, by silencing the Bach1 gene or by treatment with
cobalt protoporphyrin or heme, decreases HCV replication. Thus, miR-122 plays an important role
in the regulation of HCV replication and HO-1/Bach1 expression in hepatocytes. Down-regulation
of miR-122 and up-regulation of HO-1 may be new strategies for anti-HCV intervention and
cytoprotection.
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Hepatitis C virus (HCV) is a major cause of chronic liver disease, with an estimated 170 million
people infected world-wide and approximately 4 million infected in the USA (1). Chronic
hepatitis C (CHC) is the major cause for liver transplantations in the USA (2). Currently, there
is no approved, effective vaccine for HCV, and current treatments are expensive, unpleasant,
and relatively ineffective. Thus, there is a pressing need for improved therapeutic intervention.
The mechanisms underlying HCV-associated liver injury are imperfectly understood. Several
lines of evidence indicate that increased oxidative stress is an important pathogenetic
mechanism in CHC (3–9). HCV core and nonstructural proteins have been shown to cause
transcriptional modulation as either trans-activators or trans-suppressors of cellular signaling
pathways through interference with intracellular oxidation/reduction reactions (10–12). The
HCV core protein alters mitochondrial function and results directly in an increase in the cellular
abundance of reactive oxygen species (ROS) with consequent increases in cellular lipid
peroxidation (13–16). These results provide new insight into how chronic HCV infection leads
to hepatic injury, and provide a firm theoretical basis for the investigation of antioxidant and
cytoprotective therapies in this important disease.
HO-1 is a key cytoprotective enzyme and the rate-limiting enzyme involved in heme
degradation to bilirubin, carbon monoxide (CO), and iron (17–20). Multiple lines of evidence
support the idea that biliverdin, bilirubin, and CO contribute to the physiological functions of
HO-1, including anti-oxidative, anti-inflammatory, anti-proliferative, and anti-apoptotic
effects (21–27). HO-1 is widely distributed in tissues and robustly induced in many cells by
its substrate heme (28–30) and by numerous stressful stimuli such as ultraviolet radiation, heat
shock, inflammation, hypoxia, and various oxidative agents (31–37). The physiological
function of HO-1 has been confirmed by observations in HO-1 knockout mice (38;39) and in
one child, the product of a consanguineous mating, with severe genetic deficiency of HO-1
activity (40;41). Hence, the induction of HO-1 is one of the important events in cellular
response to pro-oxidative and pro-inflammatory insults, and also provides potent
cytoprotective and anti-oxidative effects as assessed in various models in vitro and in vivo
(21–27). Recent work by us and others indicates that Bach1, a known heme-binding protein
(42–44), forms heterodimers with small proteins of the Maf family, and that these heterodimers
repress transcription of the HO-1 gene by binding to the heme responsive elements (HeRE) in
the 5′-UTR of the HO-1 promoter. We more recently reported that heme-mediated induction
of HO-1 gene expression occurs via Bach1 and Nrf2 (a basic leucine zipper transcription factor)
in human Huh-7 cells. By using Bach1-siRNA to silence the Bach1 gene, we demonstrated
that up-regulation of HO-1 gene expression by heme was markedly increased in these cells
(45).
MicroRNAs (miRNA) are a class of small RNA molecules involved in regulation of translation
and degradation of mRNAs (46). The miRNAs typically interact with sequences within the 3′
non-coding region (NCR) of target mRNAs. Certain miRNAs are expressed ubiquitously,
whereas others are expressed in a highly tissue-specific manner (47;48). miR-122 is expressed
at high levels in the liver with more than 50,000 copies per cell, where it constitutes 70% of
the total miRNA population (47;49;50). Although it was first thought that miRNA acted solely
to down-regulate gene expression (51;52), recent results indicate that these small RNA’s, in
fact, produce both up- and down-regulation of different genes (53–55). Thus, their effects are
multidimensional, and we still have much to learn about their global effects on cells. To study
the biochemistry and biological function of miRNA, miRNA inhibitors and mimics can be
designed based on known or predicted miRNA sequences. Recently, Jopling et al reported that
miR-122 has two predicted binding sites in the HCV genome (53). The putative miR-122
binding site in the 5′-NCR of HCV genome is required for miR-122 to affect HCV RNA
abundance. Surprisingly, they failed to find that the putative 3′-NCR miR-122 binding site
affected HCV RNA replication. They reported that miR-122 neither affects HCV RNA stability
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nor RNA translation, but more likely facilitates replication of the viral RNA. The possibility
is not ruled-out that miR-122 and its antagomir also act indirectly, for example, by leading to
up-regulation of non-HCV genes, which, in turn, alter HCV gene expression.
Recently we reported that the expression of hepatic HO-1 mRNA is increased in HCV replicon
cells (56). In this study, we demonstrate that a chemically synthesized oligonucleotide, with
sequence complementary to miR-122 (miR-122 antagomir), markedly inhibited HCV RNA
replication in two Huh-7-derived HCV replicon cell lines. The antagomir up-regulated the
expression of the HO-1 gene in Huh-7 wild type cells, and in Huh-7 cells expressing HCV
proteins. Knockdown of the Bach1 gene, using Bach1-siRNA, increased HO-1 and decreased
HCV replication in both replicon cell lines.
Materials and Methods
Materials
The human hepatoma cell line, Huh-7, was purchased from the Japan Health Research
Resources Bank (Osaka, Japan). Ferric (Fe+3)-protoporphyrin IX•Cl (hemin) and cobalt
protoporphyrin (CoPP) were from Porphyrin Products (Logan, UT). Goat anti-human GAPDH
antibody was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Mouse anti-
hepatitis C core protein was purchased from Affinity BioReagents, Inc (Golden, CO). Mouse
anti-HCV NS5a was purchased from Virogen (Plantation, FL). Rabbit anti-human HO-1
antibody was purchased from Stressgen (Victoria, BC Canada). ECL-Plus was purchased from
Amersham Biosciences Corp (Piscataway, NJ). Chemically synthesized antagomir of
miR-122, non-specific control antagomir (NSCA), 2′-O-methyl-mimic miR-122, and Bach1-
siRNA were purchased from Dharmacon (Lafayette, CO). iScript Reaction Mix and SYBR
Green Mix were purchased from Bio-Rad Laboratories (Hercules, CA). CNS3 and 9-13
replicon cells were gifts from Dr. R. Bartenschlager (University of Heidelberg, Heidelberg,
Germany).
Cell Cultures
Huh-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) as previously
reported (57;58). CNS3, R-Luc, and 9–13 cells were cultured with additional antibiotics (10
μg/ml Zeocin, 5 μg/ml Zeocin, or 1 mg/ml G418), respectively. CNS3 cells stably express
HCV subgenomic proteins core-NS3 and were generated by transduction of WT Huh-7 cells
with a retroviral vector (pRV-CNS3-IGZ) carrying an expression cassette for HCV core-NS3
region encompassing nucleotide positions 342–4040 of the Con1 isolate (Fig 1A) (56;59).
Clone 9–13 carries a stably replicating HCV subgenomic (NS3-5B) replicon (Fig. 1A) (60).
The appropriate control for CNS3 and 9–13 is R-Luc, which is a stable Huh-7 cell line that
expresses a Renilla luciferase reporter protein due to transduction with the retroviral vector
pRV-R-Luc-IGZ.
Transfections
Huh-7 WT, CNS3, 9–13 cells were transfected with antagomir of miR-122, 2′-O-methyl-mimic
miR-122, Bach1-siRNA, or NSCA as described previously (57;58). In brief, cells were plated
the day before transfections and grown to 50% confluence in 12-well plates. 0–50 nM
antagomir of miR-122, 2′-O-methyl-mimic miR-122, Bach1-siRNA, or NSCA were
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Transfected cells were grown for 24–72 hours in a 37 °C incubator with 5%
CO2, after which, cells were harvested. Total RNA and protein were extracted, and stored at
−80°C for subsequent quantitative RT-PCR or Western Blot measurements. Each treatment
used at least triplicate samples.
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Total RNA from treated cells was extracted and quantitative RT-PCR was performed as
described before (45). Primers used for HCV core, HO-1, Bach1, and GAPDH quantitative
PCR were described before (45;56;58). Primers used for NS5A were: forward primer, 5′-
CGGACGTAGCAGTGCTCACTTC; reverse primer, 5′-
CGGAAGCTGGGATGGTCAAAC. We included samples without template as negative
controls, which, as expected produced negligible signals (Ct values > 35). Standard curves of
HCV core, NS5A, HO-1, Bach1, and GAPDH were constructed with results of parallel PCR
reactions performed on serial dilutions of a standard DNA (from one of the controls). Fold-
change values were calculated by comparative Ct analysis after normalizing for the quantity
of GAPDH mRNA.
Western Blot
Protein preparation and Western blots were as described before (45). In brief, total proteins
(30–50 μg) were separated on 4–15% gradient SDS-polyacrylamide gels (Bio-Rad). After
electrophoretic transfer onto PVDF membrane (Bio-Rad), membranes were blocked for 1 hour
in PBS containing 5% nonfat dry milk and 0.1% Tween-20, and then incubated for 1 hour with
primary antibody at room temperature. The dilutions of the primary antibodies were as follows:
1:500 for the NS5A antibody, and 1:2000 for anti-HCV core, and anti-GAPDH antibodies.
The membranes were then incubated for 1 hour with horseradish peroxidase-conjugated
secondary antibodies (dilution 1:10,000). Finally, the bound antibodies were visualized with
the ECL-Plus chemiluminescence system according to the manufacturer’s protocol. A Kodak
1DV3.6 computer-based imaging system (Eastman-Kodak, Rochester, NY) was used to
measure the relative optical density of each specific band obtained. Data are expressed as
percentage of the control (corresponding to the value obtained with non-transfected cells),
which were assigned a value of one.
Statistical analyses of data
Experiments were repeated at least three times with similar results. Except for Western blots,
all experiments included at least triplicate samples for each treatment group. Representative
results from single experiments are presented. Statistical analyses were performed with JMP
4.0.4 software (SAS Institute, Cary, NC). Differences in mean values were assessed by
analysis-of-variance techniques (ANOVA), with the Tukey-Kramer correction for multiple
pairwise comparisons, or Dunnett’s test versus a control. Values of P <0.05 were considered
significant.
Results
Down-regulation of HCV RNA and protein expression by antagomir of miR-122 in CNS3 and
9–13 replicon cells
miR-122 is specifically expressed and highly abundant in the human liver, where it constitutes
70% of the total miRNA population (47;50). There are two predicted binding sites for miR-122
in HCV viral 3′ and 5′ NCRs (53;55). To assess down-regulation of antagomir of miR-122 on
HCV expression, Huh-7 cells stably replicating HCV subgenomic (NS3-5B) replicon were
used (Fig. 1A). First, we compared the two cell lines stably replicating HCV core-NS3 or NS3-
NS5B proteins with wild type Huh-7 cells and cells not expressing HCV proteins (R-Luc) as
negative control (Fig. 1B&C). Next, we determined whether miR-122 inactivation would alter
the abundance of HCV RNA replication in CNS3 and 9–13 replicon cells. To inactivate
miR-122, CNS3 and 9–13 cells were transfected with 0–50 nM of chemically synthesized
antagomir of miR-122 for 48 or 72 hours. The level of HCV mRNA in the cells without
miR-122 antagomir was set equal to 1. The miR-122 antagomir reduced the abundance of HCV
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core RNA by 64% in CNS3 (Fig 2A, P<0.01), and by 84% in 9–13 replicon cells (Fig 2B,
P<0.01). The decreases were dose-dependent and time-related. Exposure of HCV replicon to
the miR-122 antagomir for 72 hours produced a greater decrease of HCV RNA expression than
exposure for 48 hours (Fig. 2C&D, P<0.05).
Using this chemically synthesized antagomir of miR-122, we also successfully down-regulated
expression of NS5A protein in 9–13 replicon cells. As little as 5 nM of miR-122 markedly
decreased HCV NS5A protein expression (Fig. 3). Thus, miR-122 plays a role to down-regulate
HCV replication in both of the HCV replicon cell lines tested.
Specific regulation of HCV RNA levels with miR-122 antagomir in 9–13 replicon cells
To confirm the specificity of gene silencing by the antagomir of miR-122, we tested HCV
NS5A mRNA expression from the cells transfected with a non-specific control antagomir
(NSCA), which is a 2′-O-melthylated randomized oligomer. We found that there were no
significant reductions of HCV mRNA levels following transfections with this NSCA, when
compared to cells that were not transfected (Fig. 4). To further assess whether miR-122 is
required for HCV RNA expression, we transfected 50 nM 2′-O-methylated-mimic-miR-122,
which contained a near perfectly matched sequence to the liver specific miR-122, into 9–13
replicon cells for 72 hours. As expected, mimic-miR-122 up-regulated HCV mRNA (1.6-fold)
expression in 9–13 replicon cells. 50 nM antagomir of miR-122 at 72 hours significantly down-
regulated NS5A mRNA levels by approximately 70% (P<0.05), when compared to non-treated
cells. Thus, silencing of the HCV RNA replication using a chemically synthesized antagomir
targeted to miR-122 was effective, specific, and selective. A similar result was found in CNS3
cells (data not shown).
An antagomir to miR-122 regulates Bach1 and HO-1 mRNA in Huh-7 cells
By computational analysis, we found at least one predicted miR-122 binding site located in
the Bach1 3′UTR (816 bp from transcription start site). No predicted miR-122 binding sites
were found in the HO-1 or Nrf2 genes. To determine whether miR-122 regulates the expression
of HO-1/Bach1 in hepatocytes, we employed antagomir of miR-122 to inactivate miR-122 in
Huh-7 WT and 9–13 cells. Transfection of 50 nM miR-122 antagomir into 9–13 cells for 72
hours significantly down-regulates the levels of Bach1 mRNAs by 53% (Fig. 5A, P<0.05) and
up-regulates the levels of HO-1 mRNA 2.2-fold as expected (Fig. 5B, P<0.05). Antagomir of
miR-122 (5–50 nM) also significantly up-regulates HO-1 mRNA levels 2.5-fold in Huh-7 wild
type cells (data not shown). These results establish that miR-122 regulates hepatic HO1 and
Bach1 gene expression.
Effects of Bach1-siRNA on up-regulation of HO-1 and down-regulation of HCV expression
Recently, we successfully up-regulated the HO-1 gene by silencing Bach1 gene expression
with Bach1-siRNA (57;58). To further investigate whether up-regulation of HO-1 gene
involved down-regulation HCV expression, we silenced the Bach1 gene with Bach1-siRNA.
50 nM Bach1-siRNA or antagomir of miR-122 were single- or co-transfected into 9–13 or
CNS3 replicon cells. The Bach1 gene was down-regulated by antagomir of miR-122 (50%) or
Bach1-siRNA (80%), but was not further down-regulated by the combination of antagomir of
miR-122 and Bach1-siRNA (Fig. 6A). HO-1 mRNA level was up-regulated ~3-fold by
antagomir of miR-122, ~ 8-fold by Bach1-siRNA, and ~11-fold by co-transfection with
antagomir of miR-122 and Bach1-siRNA (Fig. 6B). Interestingly, HCV NS5A mRNA level
was down-regulated by Bach1-siRNA (60%), which was the same amount of down-regulation
caused by antagomir of miR-122 (60%). However, there was no further down-regulation by
combined administration of Bach1-siRNA and miR-122 antagomir (Fig. 6C). We also
transfected Bach1-siRNA into CNS3 cells. As expected, silencing Bach1 gene expression, with
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Bach1-siRNA, up-regulated HO-1 gene expression nearly 1.8-fold, and reciprocally down-
regulated HCV core mRNA by over 50% (Fig. 7A & 7B).
Up-regulation of HO-1 gene expression by CoPP down-regulates HCV replication
CoPP, like heme, is known to be a potent and effective inducer of HO-1 activity in many tissues.
We up-regulated HO-1 gene expression with CoPP or heme, to further determine whether the
HO-1 gene is involved in the regulation of HCV replication in hepatocytes. CNS3 cells were
treated with 1–10 μM of CoPP for 16–72 h. As we expected, CoPP markedly up-regulated
HO-1 mRNA levels (40-fold, Fig 8A), concomitant with reciprocal reduction of the HCV core
mRNA expression (50%) in CNS3 cells in a dose-dependent (Fig 8B). HCV replication was
significantly inhibited at 1–10 μM CoPP treatment for 24 h. Exposure of HCV replicon cells
to CoPP for 24 hours produced a greater decrease of HCV RNA expression than exposure for
other times (data not shown). The expression of HCV core protein was decreased ~50% by
2.5–5 μM CoPP treatments for 24 hours (Fig 8C). HCV core protein was also decreased by 2.5
μM heme (~50%), another putative HO-1 inducer. The results presented here further confirm
that HO-1 is involved in the regulation of HCV replication in human hepatocytes.
Discussion
The major findings of this study are 1) an antagomir of miR-122 reduces the abundance of
HCV mRNA and protein in CNS3 and 9–13 cells; 2) transfection with mimic-miR-122
increases HCV levels; whereas transfection with NSCA did not change the level of HCV, when
compared to the cells that were not transfected; 3) antagomir of miR-122 decreased Bach1 and
increased HO-1 mRNA levels in CNS3 and 9–13 replicon cells; 4) silencing Bach1 with Bach1-
siRNA increases HO-1 mRNA levels and decreases HCV RNA by 50% in CNS3 and 9–13
replicon cells; and 5) up-regulation of HO-1 by CoPP significantly down-regulates HCV
mRNA and protein levels in replicon cells.
Approaches to the study of miRNA function have largely focused on the inhibition of miRNAs
with 2′-O-methylated oligonucleotides. Jopling et al employed a 2′-O-methylated miR-122
with exact complementarity to miR-122 to inactivate miR-122. In our previous study, we
silenced Bach1 and Nrf2 gene expression in hepatocytes with chemically synthesized siRNA
(57;58). By use of a chemically synthesized antagomir of miR-122, we successfully inhibited
HCV replication in two HCV replicon cell lines. Our results are consistent with the previous
finding by Jopling et al, and extend the finding to include two different replicon cell lines,
CNS3 and 9–13 cells. These results also suggest that chemically synthesized miRNA can cause
a functional inactivation of miRNA that is just as effective as the 2′-O-methylated
oligonucleotides. Also, silencing of HCV RNA replication using chemically synthesized
antagomir targeted to miR-122 was effective, specific, and selective.
Jopling et al reported that the putative miR-122 binding site in 5′ UTR of HCV genome is
required for miR-122 to affect HCV RNA abundance, whereas the 3′-UTR miR-122 binding
site is not. miR-122 neither affects HCV RNA stability nor RNA translation. It is possible that
miR-122 antagomir also acts indirectly, for example, by leading to up-regulation of non-HCV
genes, which, in turn, alter HCV gene expression. Using antagomir of miR-122 also resulted
in reduced plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a decrease in
hepatic fatty-acid and cholesterol synthesis rates (61).
HO-1 is induced as a protective mechanism to guard against heme mediated oxidative damage
to cellular lipids, proteins, and nucleoproteins. Increased oxidative stress is an important
pathogenetic mechanism in CHC (3–9). Hence, induction of HO-1 might have potential in
management of CHC. Our and other previous studies indicated that Bach1 is an HO-1 repressor
(43;57;58;62). We further investigated whether HO-1 and/or Bach1 gene expression is
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regulated by miR-122. Our results showed that miR-122 is involved the regulation of HO-1
and Bach1 gene expression in hepatocytes. These results indicate that miR-122 down-regulates
HCV replication through at least two pathways: directly facilitating the viral replication, and
indirectly through regulation of HO-1 and Bach1 gene expression.
miRNAs regulate the expression of a large number of protein-coding genes. Their primary
transcripts (pri-miRNAs) undergo multiple processing steps before reaching their final
functional form. The RNA-binding protein DiGeorge critical region-8 (DGCR8) is essential
for this first processing step of miRNA from pri-miRNA to functional form. Faller et al recently
reported that DGCR8 is a heme-binding protein (63). Heme promotes dimerization of DGCR8,
and the heme-bound DGCR8 dimer seems to trimerize upon binding pri-miRNA. It is this
complex that is active in triggering pri-miRNA cleavage, whereas the heme-free monomer is
much less active. A heme-binding region of DGCR8 inhibits the pri-miRNA-processing
activity of the monomer. This putative autoinhibition is overcome by heme. The involvement
of heme in pri-miRNA processing suggests that the gene-regulation network of miRNAs and
signal-transduction pathway involving heme might be connected. HO-1 is the rate-controlling
enzyme involved in heme degradation. It is still not clear whether heme/CoPP down-regulated
HCV replication through up-regulation of HO-1 gene expression or through regulation of
miR-122 processing.
HCV is a major cause of cirrhosis and hepatocellular carcinoma. Interferon alone or together
with ribavirin, is the cornerstone of therapy for HCV infection; however, a sizeable number of
HCV-infected individuals do not respond to this treatment and it has numerous unpleasant side
effects. Therefore, the development of new therapeutic options against HCV is a matter of
urgency. Our studies indicate that down-regulation of HCV replication using an antagomir
targeted to miR-122 is effective, specific, and selective. Increasing HO-1, by silencing the
expression of the Bach1 gene or by induction of HO-1 with CoPP/heme, also decreases HCV
replication. Thus, miR-122 plays an important role in the regulation of HCV replication and
HO-1/Bach1 expression in hepatocytes. Down-regulation of miR-122 and up-regulation of
HO-1 may be new strategies for anti-HCV intervention and cytoprotection.
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Figure 1. Organization of the HCV constructs CNS3 and 9–13
(A). Open reading frames (thick boxes) are flanked by the 5′- and 3′-UTRs (thin boxes). CNS3
is the Huh-7 cell line that expresses a zeo resistance gene (zeo), the IRES of the
encephalomyocarditis virus (E–I), which directs translation of HCV sequences from core,
envelop (E1 and E2), up to the aminoterminal domain of NS3. Replicon 9–13 is composed of
HCV-IRES, the neomycin phosphotransferase (neo) gene, E–I, HCV sequences from NS3
through NS5B, and the 3′-NTR. Panels B and C are Western blot analysis of the HCV core,
NS5A and GAPDH proteins from CNS3 and 9–13 replicon cell lines. 50 μg of protein were
separated by 4–15% SDS-polyacrylamide gel, transferred to a PVDF membrane, and probed
with anti-HCV core, anti-NS5A, and GAPDH specific antibodies. Representative results from
one of three experiments are shown.
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Figure 2. An antagomir of miR-122 reduces HCV RNA abundance in dose- and time-dependent
manner in HCV replicon cells
Chemically synthesized miR-122 antagomir was introduced into CNS3 and 9–13 replicon cells
by Lipofectamine 2000-mediated transfection, and total RNA was extracted 48 or 72 h later.
qRT-PCR analysis of HCV core (A) and NS5A (B) mRNAs of cells treated with the indicated
dose of miR-122 antagomir for 72 h as shown. Time-courses of replication of HCV core (C)
and NS5A (D) treated with 50 nM of miR-122 antagomir are shown. Normalized values of
miRNA in absence of miR-122 antagomir were set equal to 1. Data are presented as means ±
SE from three samples. * differs from no treatment or zero time, p<0.05, ** differs from no
treatment or zero time, p< 0.01.
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Figure 3. An antagomir of miR-122 reduces HCV protein abundance in HCV replicon cells
Chemically synthesized miR-122 antagomir (50 nM) was introduced into 9–13 cells using
Lipofectamine 2000-mediated transfection, and total protein was extracted 72 h later. Western
blot analysis of HCV NS5A protein treated with the indicated doses of miR-122 antagomir is
shown in panel A. 50 μg of protein were separated by 4–15% SDS-polyacrylamide gel,
transferred to a PVDF membrane, and probed with anti-NS5A and GAPDH specific antibodies.
Representative results from one of three experiments are shown. The relative NS5A protein
amounts normalized to GAPDH, the invariant control, are shown in panel B. No miR-122
antagomir was set equal to 1.
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Figure 4. An antagomir of miR-122 specifically down-regulates HCV mRNA in 9–13 cells
50 nM of non-specific control antagomir (NSCA), 2-O-methylated mimic miR-122 (mimic
miR-122), and chemically synthesized miR-122 antagomir were introduced into 9–13 cells by
Lipofectamine 2000-mediated transfection. Total RNA were extracted and the levels of HCV
NS5A mRNAs were measured by qRT-PCR. No miRNA treatment was set equal to 1. Data
are presented as means ± SE from three samples. * differs from none or other treatments,
p<0.05.
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Figure 5. An antagomir to miR-122 regulates Bach1 and HO-1 mRNAs in 9–13 cells
The miR-122 antagomir was transfected into 9–13 replicon cells by Lipofectamine 2000. Total
RNA was extracted 72 hours later. HO-1 mRNA or Bach1 levels were quantified by qRT-PCR.
A) Levels of Bach1 mRNA were down-regulated significantly in HCV replicon cells
transfected with miR-122 antagomir. B) HO-1 mRNA increased >2-fold by miR-122
antagomir, compared with no miR-122 antagomir. Data are presented as means ± SE from
three samples. * differs from non-treatments, p<0.05.
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Figure 6. Silencing Bach1 gene up-regulates HO-1 and down-regulates HCV replication in 9–13
cells
9–13 cells were transfected with 50 nM Bach1-siRNA, antagomir of miR-122, or the
combination of Bach1-siRNA and antagomir of miR-122 for 48 h, after which cells were
harvested. Bach1 (A), HO-1 (B), and NS5A (C) mRNA levels were measured by quantitative
RT-PCR, as described in the Methods. Data are presented as means ± SE from three samples.
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Figure 7. Silencing Bach1 gene up-regulates HO-1 and down-regulates HCV replication in CNS3
cells
CNS3 cells were transfected with 50 nM Bach1-siRNA, antagomir of miR-122, or the
combination of Bach1-siRNA and antagomir of miR-122 for 48 h, after which cells were
harvested. HO-1 (A) and HCV Core (B) mRNA levels were measured by quantitative RT-
PCR, as described in the Methods. Data are presented as means ± SE from three samples.
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Figure 8. Up-regulation of HO-1 by CoPP down-regulates HCV replication in CNS3 cells
A) HO-1 mRNA was increased by treatment with 5 μM CoPP for 24 h. B) HCV core mRNA
was down-regulated by CoPP in a dose-dependent fashion at 24h. C) HCV core protein was
down-regulated by CoPP and heme. CNS3 cells were treated with 1–10 μM CoPP, or 2.5 μM
heme for 24 h, after which cells were harvested. HO-1, HCV Core, and GAPDH mRNA levels
were measured by quantitative RT-PCR. HO-1 and HCV Core were normalized by GAPDH.
Data are presented as means ± SE from three samples. HCV Core and GAPDH proteins were
measured by Western Blot. 50 μg of protein were separated by 4–15% SDS-polyacrylamide
gel, transferred to a PVDF membrane, and probed with anti-HCV Core and GAPDH specific
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antibodies. Representative results from one of three experiments are shown. * differs from
DMSO (0 μM) treatment, p<0.05; ** differs from DMSO treatment, p<0.001.
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